Chronic graft versus host disease (cGVHD) is a major and frequent late complication in allogeneic stem cell transplantation recipients. Although thrombocytopenia in cGVHD patients is among the most consistent and strongest predictors of poor survival across many cGVHD studies, such correlation is still neither clearly explained nor well understood. Low platelet counts in the setting of cGVHD are associated with an increase in complications and treatment-related mortality, but usually not with higher relapse rate or engraftment failure rate. Bleeding might be occasionally increased along with, paradoxically, thrombosis. Hemostatic disorders in the context of cGVHD are significant complications with multifactorial etiology, including tissue injury with releasing microparticles, cytokine release, macrophage/monocyte clearance, CMV infection, production of transforming growth factor-beta, and low levels of thrombopoietin. Future clinical trials with agents that stimulate megakaryocytopoiesis or influence underlying impaired hemostasis mechanisms should investigate whether such interventions may improve outcomes in patients with cGVHD.
Chronic graft versus host disease (cGVHD) is a major late complication occurring in 25–80% of allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients.1 It is a systemic disorder characterized by immune deregulation, immunodeficiency, impaired organ function, development of signs and symptoms of various autoimmune or immunologic disorders, and is associated with decreased survival.1, 2, 3, 4 A low platelet count in cGVHD patients is among the most consistent and strongest negative survival predictors across cGVHD studies in both allogeneic bone marrow transplantation (alloBMT) and allogeneic peripheral stem cell transplantation (alloPSCT).2, 3, 5, 6, 7, 8, 9, 10, 11 Patients with cGVHD and persistent thrombocytopenia show poorer responses to therapy, experience higher mortality rates from infection or, less often, from hemorrhage.5, 12 Low platelet counts were also reported as a marker for a group of patients with severe cGVHD who have increased incidence of transplant-related complications and a higher mortality rate.2, 3, 5, 8, 12, 13, 14, 15 The thrombocytopenia of cGVHD is not usually associated with disease relapse or graft rejection, but significantly correlates with increased non-relapse mortality,6 indicating the existence of additional poorly understood pathophysiological mechanisms that could generate the association of thrombocytopenia and negative outcome of cGVHD. Patients with cGVHD may develop several other acquired hemostatic disorders,16, 17, 18, 19, 20 including also an increased risk for venous thrombosis in spite of higher bleeding risk.
This review analyzes and summarizes the characteristics of thrombocytopenia and other hemostatic disorders during cGVHD, focusing on identifying pathophysiological mechanisms associated with decreased platelet count and poor prognosis of cGVHD. Improved understanding of these disorders may lead to better treatments or prevention of cGVHD.
Pathophysiology of development of thrombocytopenia
Table 1 is a summary of the most important cGVHD studies showing low platelet counts as negative survival indicators. Already known pathophysiological mechanisms for development of thrombocytopenia in a non-transplant setting could also be involved in cGVHD. In general, thrombocytopenia can be caused by factors that decrease the production of platelets in the marrow or increase platelet destruction or sequestration in the peripheral circulation. Table 2 lists possible mechanisms of thrombocytopenia in the cGVDH setting.
Limited function of the stem cell graft is among the most frequent reasons for decreased platelet production in the post-transplant period. It may be associated with insufficient numbers of transplanted stem cells, relapse of hematological disorder, or persistent marrow fibrosis.13 However, transplant patients can develop isolated thrombocytopenia in the absence of disease recurrence or graft rejection.21 A combination of a recovering bone marrow, and simultaneous processes that decrease platelet survival, which might otherwise have been well tolerated, can result in persisting thrombocytopenia or secondary platelet recovery failure after alloHSCT.13 First et al.14 found that among 65 patients who had full engraftment after alloHSCT, and who survived at least 60 days after transplantation, 24 (37%) developed isolated thrombocytopenia, 9 (14%) with transient, and 15 (23%) with chronic thrombocytopenia (defined as platelet count remaining below 100 000/μl through day +120). The transient syndrome was not associated with adverse outcome, but patients with chronic thrombocytopenia had increased mortality and an increased risk of having severe acute graft versus host disease (aGVHD) and cGVHD.14 Although bleeding complications in that study contributed directly to death in just two patients with chronic thrombocytopenia, there was a significantly higher mortality among cGVHD patients with chronic thrombocytopenia than in cGVHD patients with only transient or no thrombocytopenia.14 The authors concluded that observed low platelet count may be a marker for a more severe form of cGVHD.14
Pavletic et al.2 found platelets below 100 000/μl in cGVHD patients more frequently after alloBMT (41%) than after alloPSCT (27%), but the difference was not statistically significant. Similarly, Flowers et al.22 also did not find a statistically significant difference in prevalence of thrombocytopenia in cGVHD patients after alloBMT or alloPSCT.
Although some authors speculated in earlier works that a graft-versus-stroma effect might contribute to inadequate marrow function resulting in delayed platelet recovery,23, 24 the numbers of megakaryocytes in the marrow were relatively normal in most patients with chronic thrombocytopenia and cGVHD.5, 13, 14
It was observed more recently that recipients of unmanipulated alloHSCT contain only host-type bone marrow stromal cells (BMSC) and mesenchymal stem cells (MSC).25 As MSCs can be generated as a homogenous population of cells that can be quantified, qualitatively analyzed, and ex vivo manipulated,25 and have possible clinical importance because of their supportive function for engraftment and immunosuppressive properties,26, 27 transplantation of BMSC are evolving rapidly in different settings.25, 26, 27, 28 There seems to be promise for the beneficial effect in the administration of MSCs in severe steroid refractory aGVHD,27, 29 but role of MSCs transplantation in the cGVHD setting is still unclear as it is unknown what the possible impact to thrombocytopenia and hemostatic disorders in cGVHD might be.
After primary recovery of peripheral blood counts after alloHSCT, there can be a late, persistent, isolated decrease in platelet counts called secondary failure of platelet recovery (SFPR), also associated with a poor prognosis after transplantation.21 Bruno et al.21 reported that among 1401 patients undergoing alloHSCT after primary recovery of platelet counts, SFPR not because of relapse of underlying disease was observed in 285 (20%) patients, with the median time of onset after transplantation at day 63 (range day 21–156). Among patients who developed SFPR, 141 (51%) were alive at 1 year, among them clinical extensive cGVHD occurred in 71% (101/141) and limited cGVHD in 2.5% (5/141) patients. Hazard ratio of death was significantly higher in patients who developed SFPR (hazard ratio=2.6 for alloHSCT and 2.2 for autoHSCT). No cases of graft rejection were reported in patients with SFPR.21 The factors significantly associated with SFPR were grafts from unrelated donors, regimens for GVHD prophylaxis other than cyclosporine (CSP) and methotrexate (MTX), grade 2–4 aGVHD, impaired renal or liver function, preparative regimen with combination of busulfan, cyclophosphamide, total body irradiation and infections.21
Batts and Lazarus described HSCT-associated thrombotic microangiopathy as an infrequent but challenging syndrome that may occur in alloHSCT recipients, and suggested that it is a multifactorial disorder distinct from thrombotic thrombocytopenic purpura (TTP).30 It is associated with several transplantation-related factors such as conditioning regimens, immunosuppressive agents such as tacrolimus or CSP, GVHD, and opportunistic infections.30
Hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) has been reported to occur in 13 and 9% of patients after alloHSCT.13, 31, 32 Some studies reported that using sirolimus together with calcineurin inhibitors for the treatment of refractory cGVHD could increase risk for developing thrombotic microangiopathy33 or renal insufficiency and HUS34 as toxic side effects. In a retrospective analysis of 477 HSCT patients (364 allogeneic, 83 autologous transplants) Pihusch et al.35 did not find any microangiopathic hemolytic anemia (MAHA) (defined as the simultaneous occurrence of intravascular hemolysis characterized by appearance of schistocytes in peripheral blood smears and de novo thrombocytopenia) in autologous transplant (autoHSCT) group, but there were 53 (14.6%) MAHA in alloHSCT group. MAHA in alloHSCT group was found among 48 (19.2%) aGVHD and just in 6 (3.5%) cGVHD patients.35 However, in subsequent prospective study from the same group, among 89 alloHSCT patients MAHA was found in 13 (20.0%) aGVHD and in 7 (22.6%) cGVHD patients.36
Drugs such as MTX, ganciclovir, and trimethoprim-sulfamethoxazole that are frequently used after alloHSCT may be associated with delayed platelet engraftment or secondary platelet failure.14, 37, 38, 39, 40 Bruno et al.21 found that regimens for GVHD prophylaxis different from the standard combination with CSP and MTX were associated with SFPR after alloHSCT. However, other studies did not find differences in platelet transfusion requirements when comparing the combination of CSP and MTX to CSP alone.38 Mycophenolate mofetil is an established drug for treatment of both acute and chronic GVHD, and it could cause thrombocytopenia as a side effect.41
Other drugs may cause thrombocytopenia by inducing antibodies against megakaryocytes and/or platelets, such as acetaminophen, amphotericin B, vancomycin, ranitidine, fluconazole, heparin, and others.42 Many such drugs are used in cGVHD patients, so it is important to consider drug-induced thrombocytopenia as a possible cause of low platelet counts in the cGVHD setting.
In addition to drug-induced antiplatelet antibodies and identification of a number of other different autoantibodies and alloantibodies in cGVHD patients,43 development of platelet-specific auto- or allo-antibodies have been reported in cGVHD patients.5, 44, 45, 46 Anasetti et al.5 assessed mechanisms of persistent thrombocytopenia in 20 patients who were between 60 and 649 days (median 90) after alloBMT; among them 17 had isolated thrombocytopenia, 10 aGVHD, and 6 cGVHD.5 Platelet survival studies showed that platelets persisted in the circulation for a shorter period of time in patients with GVHD, and in all studied patients a direct relationship between platelet survival and platelet count was observed.5 Moreover, platelet autoantibodies were found in five of six patients with acute or chronic GVHD, and in none of six patients without GVHD.5 The investigators concluded that persistent thrombocytopenia after marrow transplantation is most often because of increased platelet destruction mediated by multiple mechanisms and that the immune deregulation accompanying GVHD may produce autoimmune thrombocytopenia.5 Platelet count increments after transfusions in GVHD patients have also been found to be less than in controls without GVHD, supporting conclusion that GVHD patients may have thrombocytopenia mainly because of decreased platelet survival in the peripheral blood.13
Banaji et al.47 assessed the effect of splenectomy on engraftment and platelet transfusion requirements in 67 alloBMT patients with chronic myelogenous leukemia. Comparing with patients splenectomized before transplantation, it was reported that the presence of the spleen was an important factor in delaying recovery of platelet counts after alloHSCT. However, among unsplenectomized patients the splenic size did not affect the speed of platelet recovery or platelet transfusion requirements.47 Another study showed a trend for splenectomized patients to have a faster recovery of platelet counts compared with non-splenectomized controls, with similar incidence of cGVHD among splenectomized and non-splenectomized patients.48 Anasetti et al.5 did not find a relationship between platelet count and splenic pooling, and they concluded that hypersplenism did not significantly contribute to thrombocytopenia in their study. Others described two patients who underwent splenectomy because of resistant immune cytopenias after alloHSCT, resulting in improvement of platelet and other blood counts, but severe late infections compromised the outcome of that approach.49
It is well known that severe thrombocytopenia may occur in patients with sepsis in the non-transplant setting.50 As patients with cGVHD have an increased risk for infection—in one recently published study 57% of cGVHD patients developed infections with mortality rate of 27%51—it is possible that some common mechanisms contribute to the thrombocytopenic states found in infections or inflammation and cGVHD. One proposed mechanism is a ‘cytokine storm effect’, with increased levels of cytokines that may activate the monocyte/macrophage system, causing increased removal of platelets from circulation.21, 52, 53, 54 CMV infection has been shown to be associated with poor marrow graft function after alloHSCT.55 CMV has a direct toxic effect on marrow stem cell maturation,56 and it can disturb effective production of platelets after HSCT.57 Isolated thrombocytopenia has also been observed during CMV infection.58 CMV modulates various aspects of immune response, and different mechanisms of marrow suppression have been proposed, such as direct infection of hematopoietic progenitors or stromal cells, abnormal gene expression, and immune reaction against the infected cells.59, 60, 61, 62 More recent studies in long-term bone marrow cultures indicate that BMSC are targets of CMV infection and that CMV replicates in BMSCs.63 In addition, experiments show that BMSCs are permissive to CMV infection, and that CMV significantly alters the function of BMSCs.63 It is likely that in the pathobiology of CMV infection, natural killer T cells and CD1d molecules might be protective against CMV-induced suppression of hematopoiesis, according to the results in experimental animals, which may lead to the new strategies in treatment of CMV-induced perturbation of hematopoiesis in immunocompromised patients.64 In addition to that, other therapeutic approaches to CMV infection and disease have been extensively investigated in recent years.65, 66, 67
Some other viruses may also cause thrombocytopenia by various mechanisms, such as Epstein-Barr virus, human herpes virus-6, parvovirus B19.68, 69, 70, 71, 72 CMV or human herpes virus-6 in post-alloBMT patients may also cause vascular endothelial injury, which could lead to development of thrombotic microangiopathy.73
It is possible that similar mechanisms are responsible for the thrombocytopenia in infection and cGVHD. Serum cytokine levels including granulocyte colony-stimulating factor (G-CSF), macrophage CSF (M-CSF), interleukin-1α, interleukin-1β, and interleukin-6 may be significantly increased in both conditions, and may lead to the activation of monocytes and macrophages, leading to the increased platelet consumption.13 In addition, it was observed that both granulocyte–macrophage-CSF and M-CSF in pharmacologic doses may reduce platelet counts in a dose-dependent manner or delay platelet recovery after chemotherapy.54, 74, 75, 76 Additionally, though donor treatment with G-CSF may decrease the ability of donor T cells to induce aGVHD, it may also contribute to increase the severity of cGVHD.77, 78 The role of transforming growth factor-beta (TGF-β) in this process was assessed in a murine model of aGVHD and cGVHD. It was shown that the production of TGF-β by donor T cells early after HSCT attenuates aGVHD and is important for graft versus leukemia effects, and that the production of TGF-β late after HSCT is mostly from mononuclear cells and increases the severity of cGVHD.1, 79 TGF-β suppresses megakaryopoiesis,80 is a potent immunosuppressive cytokine, and has role in development of tissue fibrosis.81 Liem et al.81 found that TGF-β levels correlate significantly with platelet and leukocyte count in BMT recipients and that cGVHD is associated with increased level of serum TGF-β independent of platelet or leukocyte count. Recent work has provided evidence for the activation of TGF-β in a variety of cells and tissues infected by CMV, inducing further downstream signaling that could alter vascular function and lead to development of fibrosis.82 Such results might suggest another possibly important pathophysiological mechanism that link together cGVHD, CMV infection, TGF-β, and thrombocytopenia. Thrombocytopenia because of low thrombopoietin (TPO) level is generally thought to be relatively rare; however, it has not been thoroughly investigated in the cGVHD setting. Hirayama et al.83 described two cGVHD patients with low platelet counts and strong correlations of platelet and megakaryocyte numbers with TPO concentrations in peripheral blood. They concluded that low TPO production may be responsible for thrombocytopenia in some cGVHD patients.
Thrombophilic and bleeding predisposition in cGVHD
Pihusch et al.84 found that patients with cGVHD had a seven-fold increased ratio of circulating platelet microparticles comparing to healthy controls, whereas alloHSCT patients without cGVHD had a normal ratio of circulating microparticles. Circulating microparticles are membrane vesicles mainly derived from platelets, but also from erythrocytes, leukocytes, and endothelial cells,85 released after intensive cell activation, which enhance enzymatic reactions of the coagulation cascade by providing a large phospholipid surface,86, 87, 88, 89 and activating platelets,90 thereby increasing the risk of thrombosis. Microparticles are, for example, associated with prothrombotic conditions such as heparin-induced thrombocytopenia,86 TTP,91 paroxysmal nocturnal hemoglobinuria,92 and myocardial infarction.93 Moreover, microparticles produce proinflammatory changes in the endothelium, increase expression of adhesion molecules90 and have strong mitogenic effects on smooth muscle cells.94 Leukocytes and endothelial cells might also generate microparticles that have a functional role and may modulate activities of other cells.95 For example, leukocyte-derived microparticles deliver prothrombotic tissue factor to developing thrombus, and target activating platelets by binding platelet P-selectin.95 According to a recently published study, leukocyte-derived microparticles also act as a novel platelet agonist targeting GPIbα, a platelet-adhesion receptor important for initiation of clot formation by binding von Willebrand factor (vWF); such leukocyte–platelet interactions are amplified in situation when neutrophils are also activated.95, 96 It is important to note the link between vWF, endothelial injury, and cGVHD described by Biedermann et al.97 They found that cGVHD patients have extensive loss of microvessels in affected tissues and increased circulating vWF concentrations, concluding that vWF was released from vascular endothelial cells injured in process of cGVHD.97 In summary, involvement of microparticles formation in coagulation, inflammation, and vascular problems, as well as in other platelet–leukocyte–endothelial processes and interactions,98 could have important roles in the pathophysiology of tissue damage found in cGVHD.84
Acquired platelet storage pool disease
Pihusch et al.84 observed that platelets were activated in patients after alloHSCT, but they also found loss of dense platelet granules and a reduced surface expression of the major collagen receptor GP Ia/IIa. Platelet dense bodies contain ADP, ATP, serotonin, and divalent cations, and are essential for primary hemostasis. A defect of dense bodies, termed ‘storage pool deficiency’, is usually inborn, but patients following alloHSCT may have an acquired storage pool deficiency.84 The integrin receptor GP Ia/IIa is important in the adhesion of platelets to collagen,99 leading to platelet fixation and activation. A reduced surface expression of this receptor has been described in inborn platelet abnormalities100 and in myelodysplastic syndromes101 and leads to an increased bleeding risk. Although the observed HSCT-associated storage pool disease and the GP Ia/IIa deficiency may increase the bleeding tendency in HSCT patients, they have not been associated with cGVHD, platelet count, antiviral, antifungal, or immunosuppressive drugs. Therefore, these investigators suggest that they could be the consequence of a perturbation of platelet synthesis after alloHSCT.84
Bleeding and thrombosis in cGVHD
In another large study Pihusch et al.35 retrospectively analyzed hemostatic complications among 447 HSCT patients. The 364 alloHSCT patients had a higher incidence and severity of hemorrhagic complications than autoHSCT patients, despite a similar duration of thrombocytopenia in both groups. Subgroup analysis showed that this was due to GVHD: patients with aGVHD greater than grade I had a 3-fold higher risk of bleeding, cGVHD patients had a 4-fold higher risk, with an 11-fold risk of severe hemorrhage. Such GVHD-associated bleeding was mostly localized in GVHD-affected organs such as skin and gastrointestinal tract; it correlated with an increased mortality, and could not be explained by demonstrated disturbances in hemostatic mechanisms. The authors concluded that aGVHD and cGVHD strongly aggravated bleeding risk by destruction of epithelium and hyperperfusion and proliferation of the blood vessels, which is typical for tissues affected by GVHD.35 In addition, they observed that hemorrhagic cystitis was strongly associated with both aGVHD and cGVHD. In the same study among 447 HSCT patients (364 alloHSCT), venous thromboembolism (VTE), including catheter thrombosis, extremity thromboses, or pulmonary embolisms, occurred mostly later after transplantation and depended on the type of transplantation. AutoHSCT patients had a 4.8% incidence, alloHSCT patients with aGVHD had a 6.8% incidence, and cGVHD patients had an 8.1% incidence of VTE.35 cGVHD and treatment with steroids were the most important risk factors for VTE.35 The authors suggested that cytokines that modulate endothelial hemostatic function could be responsible for VTE in cGVHD. For example, tumor necrosis factor-alpha, which is important in the pathophysiology of GVHD, enhances the production of the prothrombotic plasminogen activator inhibitor I102 and tissue factor, and decreases the tissue factor pathway inhibitor, thus increasing possibility of the development of VTE.35 Other work from the same group of authors prospectively studied the impact of GVHD and of thrombophilic gene mutations on hemostatic complications and on transplant-related toxicity in 89 alloHSCT patients.36 They again reported increased risk for venous thrombosis and pulmonary embolism among cGVHD patients, whereas the risk for catheter thrombosis was not affected by GVHD.36 Risk of bleeding was increased in both aGVHD and cGVHD patients, which was explained by differences in the incidence of gastrointestinal bleeding.36 In that work, thrombophilic gene mutations and polymorphisms did not influence either the incidence of any of the major transplant-related complications, including aGVHD and cGVHD, or the bleeding incidence.36 Among patients with thromboembolic complications those with catheter thromboses and hepatic veno-occlusive disease showed an increased frequency of the 4G allele of the PAI-1 gene, whereas other tested thrombophilic gene mutations and polymorphisms had no impact on the incidence of VTE complications among alloHSCT patients. Authors concluded that thrombophilic gene mutations have only a moderate influence on hemostatic complications in alloHSCT patients, and that a possible explanation might be because of major immunologic impact of GVHD on hemostasis in the alloHSCT setting.36
In addition to that, in cGVHD patients, the simultaneous presence of a thrombophilic state, because of circulating microparticles or activated platelets, and the HSCT-associated platelet defect, which is attributed to an increased bleeding tendency, may seem paradoxical. However, observed impaired platelet function may mainly disturb a primary or immediate hemostasis, whereas the huge phospholipid surface provided by microparticles mainly activates the plasma coagulation cascade, which is crucial in the pathogenesis of VTE. Therefore, patients with cGVHD may have an increased bleeding tendency and a prothrombotic state at the same time.35, 84 It should be also noted that thalidomide, a drug that is used in the treatment of cGVHD,103 has prothrombogenic side effects, which may further increase the risk for development of VTE in cGVHD patients.
Other acquired hemostatic disorders in cGVHD
Other acquired hemostatic disorders in cGVHD patients are rare and are described in several case reports (Table 3). Seidler et al.16 described a male patient who developed acquired hemophilia A (acquired factor VIII inhibitor) with clinical bleeding diathesis 2 years after alloBMT for chronic myelogenous leukemia in association with a flare of cGVHD.16 The patient had no history of bleeding and had normal coagulation tests in the past. The patient responded well to prednisone therapy with disappearance of FVIII inhibitor, regression of cGVHD, and no further bleeding manifestations.16 Lazarchick and Green17 described a patient with acquired von Willebrand's disease and cGVHD. The patient was transplanted because of acute myelogenous leukemia and had worsening of cGVHD 6 months after alloHSCT with bleeding manifestations. He was found to have no measurable FVIII activity and a mixing study was compatible with the presence of inhibitor. It was first assumed that he developed acquired hemophilia A. However, further evaluation defined that he had also very low vWF antigen and ristocetin cofactor activity, with antiristocetin cofactor inhibitor and almost complete absence of all vWF multimers, consistent with the diagnosis of acquired von Willebrand's disease.17 He was treated with combination of inhibitor removal by apheresis followed by infusion of FVIII and vWF concentrate, which resulted in normalization of coagulation parameters and cessation of bleeding. He died of progressive cGVHD with multi-organ system failure.17 Antiphospholipid syndrome (APS) is characterized by antiphospholipid antibodies, thrombosis, thrombocytopenia, and/or recurrent fetal loss. Antiphospholipid antibodies are also among GVHD-associated autoantibodies, and though some studies have not found them to be pathologic,104 an occasional case report has found an association between antiphospholipid antibodies and development of APS with thrombotic manifestations in cGVHD.20 Catastrophic APS, an unusual and potentially lethal variant of the APS has also been described in cGVHD setting.19 Kasamon et al.19 described a female patient who developed catastrophic APS after alloHSCT for acute lymphoblastic leukemia. She developed multi-organ thrombosis and organ failure together with antiphospholipid antibodies and cGVHD and died. Ritchie et al.18 described passive donor-to-recipient transfer of APS following the onset of cGVHD. In that case, a male patient with CML underwent alloHSCT. His sister was the donor who had documented systemic lupus erythematous and APS. Six months post transplant he developed cGVHD of liver, and anticardiolipin antibodies, lupus anticoagulant and antinuclear antibody were positive at 8, 12, and 16 months, which was identical to that of the donor. He did not develop any clinical evidence of systemic lupus erythematous, however, at 53 months after transplantation he experienced cerebrovascular thrombosis, which was successfully treated.18
Many different mediators are involved in platelet production and activation. These mediators may be of interest in future assessments of coagulation processes and disorders in cGVHD patients. Furthermore, a very recently published paper of Flaumenhaft et al.105 emphasized the importance of platelet-derived microparticles in many different pathological processes; it should be interesting to investigate their possible role in pathogenesis of cGVHD. In addition, it would be important to study the relationship of thrombocytopenia and disorders of hemostasis in the context of various cGVHD clinical presentations in light of the new NIH cGVHD classification.106
As a variety of new agents are currently being tested as new options for the management of thrombocytopenia, it would be interesting to determine their effect on thrombocytopenia in cGVHD. Pharmaceutical methods to stimulate the production of platelets from megakaryocytes (analogous to erythropoietin to stimulate red blood cell production or G-CSF to stimulate granulocyte production) have long been sought to treat thrombocytopenia. The first efforts to stimulate platelet production by use of recombinant hormone TPO or a pegylated recombinant partial TPO peptide ‘human megakaryocyte growth and development factor’ (PEG-rHuMGDG) resulted in faster recovery of normal platelet counts in chemotherapy recipients.107 However, the use of these drugs was complicated by development of antibodies that cross-reacted to native TPO, and in the case of PEG-rHuMGDG recipients, neutralized TPO (resulting in prolonged thrombocytopenia).108 For this reason, subsequent drug development in this field has focused on finding molecules that either interact with the TPO receptors on the megakaryocyte surface, or stimulate the downstream intracellular signaling pathway that is activated by TPO. Two such molecules have been identified that act to increase platelet counts by stimulating platelet production in megakaryocytes: eltrombopag, a synthetic molecule with oral bioavailability that interacts non-competitively with the TPO receptor to increase thrombopoiesis,109 and romiplostim, a novel peptide in which two IgG Fc domains are fused to four copies of a TPO-mimetic peptide.110 Both romiplostim and eltrombopag seem to be effective in raising platelet counts and have been well tolerated in clinical trials to date.111, 112, 113 It remains to be seen whether use of either of these agents would be of value to patients with thrombocytopenia and cGVHD.
Another possible area of interest is testing BMSC infusion in the context of cGVHD and its hemostatic impairments; anecdotal but not well-documented partial responses in cGVHD patients after BMSC transplantation have been already reported.27 In the context of anti-inflammatory and immunosuppressive effect of BMSC it would be interesting to assess its effect in the treatment of cGVHD as well as its effect on low platelet counts and other hemostatic disorders in cGVHD patients.
In summary, thrombocytopenia and impaired hemostasis in cGVHD are significant complications. These disorders may be closely implicated in the cGVHD pathogenesis and could represent targets of potential interest for therapeutic intervention. Design and conduct of future clinical trials with agents that stimulate megakaryocytopoiesis or influence underlying hemostatic deregulation should be explored; however, such studies must also consider risks associated with concurrent hemostatic disturbance and complex clinical factors in the context of the cGVHD setting.
Conflict of interest
The authors declare no conflict of interest.
Baird K, Pavletic SZ . Chronic graft versus host disease. Curr Opin Hematol 2006; 13: 426–435.
Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol 2005; 78: 265–274.
Lee SJ, Vogelsang G, Flowers ME . Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215–233.
Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ . Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 2–10.
Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ . Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 1989; 73: 1054–1058.
Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003; 102: 802–809.
Akpek G, Zahurak ML, Piantadosi S, Marglois J, Doherty J, Davidson R et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219–1226.
Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700.
Arora M, Burns LI, Davies SM, MacMillan ML, Defor TE, Miller WJ et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 2003; 9: 38–45.
Arora M, Nagaraj S, Wagner JE, Barker JN, Brunstein CG, Burns LJ et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant 2007; 13: 1145–1152.
Pasquini MC . Impact of graft-versus-host disease on survival. Best Pract Res Clin Haematol 2008; 21: 193–204.
Sullivan KM, Withenspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S et al. Prednisone and azathioprine compared to prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546–554.
Nash RA, Gooley T, Davis C, Appelbaum FR . The problem of thrombocytopenia after hematopoietic stem cell transplantation. Oncologist 1996; 1: 371–380.
First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM . Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood 1985; 65: 368–374.
Pavletic SZ, Lee SJ, Socie G, Vogelsang G . Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 2006; 38: 645–651.
Seidler CW, Mills LE, Flowers MED, Sullivan KM . Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease. Am J Hematol 1994; 45: 240–243.
Lazarchick J, Green C . Acquired von Willebrand's disease following bone marrow transplantation. Ann Clin Lab Sci 1994; 24: 211–215.
Ritchie DS, Sainani A, D’Souza A, Grigg AP . Passive donor-to-recipient transfer of antiphospholipid syndrome following allogeneic stem-cell transplantation. Am J Hematol 2005; 79: 299–302.
Kasamon KM, Drachenberg CI, Rapoport AP, Badros A . Catastrophic antiphospholipid syndrome: atypical presentation in the setting of chronic graft versus host disease: case report and review of the literature. Haematologica 2005; 90: e50–e53.
Sohngen DHA, Meckenstock G, Aul C, Wolf HH, Schneider W, Specker C et al. Antiphospholipid syndrome complicating chronic graft-versus-host disease after allogeneic bone marrow transplantation. Am J Hematol 1994; 47: 143–144.
Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 154–162.
Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415–419.
Holmberg LA, Torok-Storb B . Possible role of a defective hematopoietic microenvironment for the pathogenesis of bone marrow failure. In: Raghavachar A, Schrezenmeier H, Frickhofen N (eds). Aplastic Anemia: Current Perspectives on the Pathogenesis and Treatment. Blackwell MZV: Vienna, Austria, 1993, pp 58–66.
Peralvo J, Bacigalupo A, Pittaluga PA, Occhini D, Van Lint MT, Frassoni F et al. Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 279–285.
Koç ON, Lazarus HM . Mesenchymal stem cells: heading into the clinic. Bone Marrow Transplant 2001; 27 (3): 235–239.
Lazarus HM, Koç ON, Devine SM, Curtin P, Maziarz RT, Holland HK et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11 (5): 389–398.
Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81 (10): 1390–1397.
Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18 (2): 307–316.
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II∣ study. Lancet 2008; 371 (9624): 1579–1586.
Batts ED, Lazarus HM . Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709–719.
Holler E, Kolb HJ, Hiller E, Mraz W, Lehmacher W, Gleixner B et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus host disease after HLA-identical bone marrow transplantation. Blood 1989; 73: 2018–2024.
Rabinowe SN, Soiffer RJ, Tarbell NJ, Neuberg D, Freedman AS, Seifter J et al. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 1991; 77: 1837–1844.
Jurado M, Vallejo C, Pérez-Simón JA, Brunet S, Ferra C, Balsalobre P et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 701–706.
Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 47–55.
Pihusch R, Salat C, Schmidt E, Göhring P, Pihusch M, Hiller E et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74: 1303–1309.
Pihusch M, Lohse P, Reitberger J, Hiller E, Andreesen R, Kolb HJ et al. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004; 78 (6): 911–918.
Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225–1230.
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179–184.
Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD . Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173–178.
Basara N, Blau WI, Römer E, Rudolphi M, Bischoff M, Kirsten D et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22 (1): 61–65.
Diz-Küçükkaya R, Gushiken FC, López JA . Thrombocytopenia. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT (eds). Williams Hematology, 7th edn. The McGraw-Hill Companies, Inc.: New York, NY, 2006 pp 1749–1783.
Kapur R, Ebeling S, Hagenbeek A . B-cell involvement in chronic graft-versus-host disease. Haematologica 2008; 93: 1702–1711.
Benda H, Panzer S, Kiefel V, Mannhalter C, Hinterberger W, Lechner K . Identification of the target platelet glycoprotein in autoimmune thrombocytopenia occurring after allogeneic bone marrow transplantation. Blut 1989; 58: 151–153.
Bierling P, Pignon JM, Kuentz M, Mitjavila MT, Fromont P, Barbu V et al. Thrombocytopenia after bone marrow transplantation caused by a recipient origin Br(a) allo-antibody: presence of mixed chimerism 3 years after the graft without hematologic relapse. Blood 1994; 83: 274–279.
Evenson DA, Stroncek DF, Pulkrabek S, Perry EH, Radford J, Miller JS et al. Posttransfusion purpura following bone marrow transplantation. Transfusion 1995; 35: 688–693.
Banaji M, Bearman SI, Buckner CD, Clift RA, Bensinger WI, Petersen FB et al. The effects of splenectomy on engraftment and platelet transfusion requirements in patients with chronic myelogenous leukemia undergoing marrow transplantation. Am J Hematol 1986; 22: 275–283.
Kalhs P, Schwarzinger I, Anderson G, Mori M, Clift RA, Storb R et al. A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995; 86: 2028–2032.
Proleznik Zupan I, Prentice HG, Pretnar J, Zver S, Cernelc P . Splenectomy for severe autoimmune cytopenias after allogeneic stem cell transplantation: case report. Int J Hematol 2005; 82: 75–78.
Poskitt TR, Poskitt PK . Thrombocytopenia of sepsis: the role of circulating IgG-containing immune complexes. Arch Intern Med 1985; 145: 891–894.
Yamasaki S, Heike Y, Mori S, Fukuda T, Maruyama D, Kato R et al. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. Transpl Infect Dis 2008; 10: 252–259.
Baker GR, Levin J . Transient thrombocytopenia produced by administration of macrophage colony-stimulating factor: investigations of the mechanism. Blood 1998; 91: 89–99.
Nash RA, Burstein SA, Storb R, Yang W, Abrams K, Appelbaum FR et al. Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: increased destruction of circulating platelets. Blood 1995; 86: 1765–1775.
Johnson CW, Nachtman JP, Cimprich RE, Moon HL, Mills SE, Beckendorf J et al. Clinical and histopathological effects of M-CSF in laboratory animals. Int Rev Exp Pathol 1993; 34: 189–204.
Torok-Storb B, Boeckh M, Hoy C, Leisenring W, Myerson D, Gooley T . Association of specific cytomegalovirus (CMV) genotypes with death from myelosuppression after marrow transplantation. Blood 1997; 90: 2097–2102.
Forman SJ, Zaia JA, Racklin BC, Wright CL, Blume KG . In vitro suppression of bone marrow growth (CFU-c) by human cytomegalovirus antigen stimulated mononuclear cells and supernatant. Blood 1985; 66: 259a.
Verdonck LF, van Heugten H, de Gast GC . Delay in platelet recovery after bone marrow transplantation: impact of cytomegalovirus infection. Blood 1985; 66: 921–925.
Rosenfeld SJ, Young NS . Viruses and bone marrow failure. Blood Rev 1991; 5: 71–77.
Sing GK, Ruscetti FW . Preferential suppression of myelopoiesis in normal human bone marrow cells after in vitro challenge with human cytomegalovirus. Blood 1990; 75: 1965–1973.
Maciejewski JP, Bruening EE, Donahue RE, Mocarski ES, Young NS, Jeor St SC . Infection of hematopoietic progenitor cells by human cytomegalovirus. Blood 1992; 80: 170–178.
Duncombe AS, Grundy JE, Prentice HG, Brenner MK . IL2 activated killer cells may contribute to cytomegalovirus induced marrow hypoplasia after bone marrow transplantation. Bone Marrow Transplant 1991; 7: 81–87.
Apperley JF, Dowding C, Hibbin J, Buiter J, Matutes E, Sissons PJ . The effect of cytomegalovirus on hemopoiesis: in vitro evidence for selective infection of marrow stromal cells. Exp Hematol 1989; 17: 38–45.
Smirnov SV, Harbacheuski R, Lewis-Antes A, Zhu H, Rameshwar P, Kotenko SV . Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection: implications for hematopoiesis, self-renewal and differentiation potential. Virology 2007; 360 (1): 6–16.
Broxmeyer HE, Dent A, Cooper S, Hangoc G, Wang ZY, Du W et al. A role for natural killer T cells and CD1d molecules in counteracting suppression of hematopoiesis in mice induced by infection with murine cytomegalovirus. Exp Hematol 2007; 35 (Suppl 1): 87–93.
Zhong J, Khanna R . Vaccine strategies against human cytomegalovirus infection. Expert Rev Anti Infect Ther 2007; 5 (3): 449–459.
Takami A, Mochizuki K, Ito S, Sugimori C, Yamashita T, Asakura H et al. Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation. Transplant Proc 2007; 39 (1): 237–239.
Sun HY, Wagener MM, Singh N . Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8 (10): 2111–2118.
Walter RB, Hong TC, Bachli EB . Life-threatening thrombocytopenia associated with acute Epstein-Barr virus infection in an older adult. Ann Hematol 2002; 81: 672–675.
Isomura H, Yoshida M, Namba H, Fujiwara N, Ohuchi R, Uno F et al. Suppressive effects of human herpesvirus-6 on thrombopoietin-inducible megakaryocytic colony formation in vitro. J Gen Virol 2000; 81: 663–673.
Bhattacharyya J, Kumar R, Tyagi S, Kishore J, Mahapatra M, Choudhry VP . Human parvovirus B19-induced acquired pure amegakaryocytic thrombocytopenia. Br J Haematol 2005; 128: 128–129.
Sipahi T . Human parvovirus B19 associated with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2005; 22: 345–346.
Eid AJ, Brown RA, Patel R, Razonable RR . Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 2006; 43: 40–48.
Takatsuka H, Wakae T, Mori A, Okada M, Fujimori Y, Takemoto Y et al. Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant 2003; 31: 475–479.
Bunn Jr PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13: 1632–1641.
Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F et al. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. J Clin Oncol 1994; 12: 2667–2676.
Sanda MG, Yang JC, Topalian SL, Groves ES, Childs A, Belfort Jr R et al. Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. J Clin Oncol 1992; 10: 1643–1649.
Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705–4709.
Storek J, Witherspoon RP, Maloney DG, Chauncey TR, Storb R . Improved reconstitution of CD4 T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow. Blood 1997; 89: 3891–3893.
Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don A et al. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood 2005; 106: 2206–2214.
Sakamaki S, Hirayama Y, Matsunaga T, Kuroda H, Kusakabe T, Akiyama T et al. Transforming growth factor-beta1 (TGF-beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity. Blood 1999; 94: 1961–1970.
Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E . Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 1999; 67: 59–65.
Tabata T, Kawakatsu H, Maidji E, Sakai T, Sakai K, Fang-Hoover J et al. Induction of an epithelial integrin alphavbeta6 in human cytomegalovirus-infected endothelial cells leads to activation of transforming growth factor-beta1 and increased collagen production. Am J Pathol 2008; 172 (4): 1127–1140.
Hirayama Y, Sakamaki S, Tsuji Y, Sagawa T, Chiba H, Matsunaga T et al. Thrombopoietin concentrations in peripheral blood correlated with platelet numbers in two patients with thrombocytopenia by chronic graft-versus-host disease. Am J Hematol 2003; 73: 285–289.
Pihusch R, Wegner H, Salat C, Pihusch M, Holler E, Kolb HJ et al. Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 381–387.
Van Wijk MJ, vanBavel E, Sturk A, Nieuwland R . Microparticles in cardiovascular disease. Cardiovasc Res 2003; 59: 277–287.
Hughes M, Hayward CP, Warkentin TE, Horsewood P, Chorneyko KA, Kelton JG . Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000; 96: 188–194.
Warner MN, Pavord S, Moore JC, Warkentin TE, Hayward CP, Kelton JG . Serum-induced platelet procoagulant activity: an assay for the characterization of prothrombotic disorders. J Lab Clin Med 1999; 133: 129–133.
Gilbert GE, Sims PJ, Widemer T, Furie B, Furie BC, Shattil SJ . Platelet-derived microparticles express high affinity receptors for Factor VIII. J Biol Chem 1991; 266: 17261–17268.
Sims PJ, Faioni EM, Wiedmer T, Shattil SJ . Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205–18212.
Barry OP, Practico D, Lawson JA, Fitzgerald GA . Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118–2127.
Galli M, Grassi A, Barbui T . Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Hemost 1996; 75: 427–431.
Hugel B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet JM et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 3451–3456.
Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841–848.
Weber A, Koppen HO, Schror K . Platelet-derived microparticles stimulate coronary artery smooth muscle cell mitogenesis by a PDGF-independent mechanism. Thromb Res 2000; 98: 461–466.
Andrews RK, Berndt MC . Microparticles facilitate neutrophil/platelet crosstalk. Blood 2008; 112: 2174–2175.
Pluskota E, Woody NM, Szpak D, Ballantyne CM, Soloviev DA, Simon DI et al. Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. Blood 2008; 112: 2327–2335.
Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359: 2078–2083.
Pihusch V, Rank A, Steber R, Pihush M, Pihush R, Toth B et al. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients. Transplantation 2006; 81: 1405–1409.
Saelman EUM, Nieuwenhuis HK, Hese KM, de Groot PG, Heijnen HF, Sage EH et al. Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood 1994; 83: 1244–1250.
Handa M, Watanabe K, Kawai Y, Kamata T, Koyama T, Nagai H et al. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Hemost 1995; 73: 521–528.
Nieuwenhuis HK, Sakariassen KS, Houdijk WP, Nievelstein PF, Sixma JJ . Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 1986; 68: 692–695.
Nawroth PP, Stern DM . Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740–745.
Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96: 3995–3996.
Mengarelli A, Minotti C, Palumbo G, Arcieri P, Gentile G, Iori AP et al. High levels of antiphospholipid antibodies are associated with cytomegalovirus infection in unrelated bone marrow and cord blood allogeneic stem cell transplantation. Br J Haematol 2000; 108: 126–131.
Flaumenhaft R, Dilks JR, Richardson J, Alden E, Patel-Hett SR, Battinelli E et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood 2009; 113: 1112–1121.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y . Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100: 728–730.
Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241–3248.
Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 4739–4741.
Wang B, Nichol JL, Sullivan JT . Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76: 628–638.
Tiu RV, Sekeres MA . The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes. Expert Opin Biol Ther 2008; 8: 1021–1030.
Stasi R, Evangelista ML, Amadori S . Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68: 901–912.
Kobos R, Bussel JB . Overview of thrombopoietic agents in the treatment of thrombocytopenia. Clin Lymphoma Myeloma 2008; 8: 33–43.
We thank Drs Georgia Vogelsang and Ronald Gress for their valuable comments and the critical review of the manuscript. This work is supported in part by the intramural program of the National Cancer Institute, Center for Cancer Research. Disclaimer: The opinions expressed here are those of the authors and do not represent the official position of the National Institutes of Health or the US Government.
About this article
Cite this article
Pulanic, D., Lozier, J. & Pavletic, S. Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. Bone Marrow Transplant 44, 393–403 (2009). https://doi.org/10.1038/bmt.2009.196
- chronic graft versus host disease
- hemostatic disorders
Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant
British Journal of Haematology (2018)
Posttransplant Intramuscular Injection of PLX-R18 Mesenchymal-Like Adherent Stromal Cells Improves Human Hematopoietic Engraftment in A Murine Transplant Model
Frontiers in Medicine (2018)
Bone Marrow Transplantation (2017)
Dysfonctionnement du greffon et érythroblastopénie après allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
Bulletin du Cancer (2016)
Frontiers in Immunology (2016)